Recent revelations about the presence of benzene in benzoyl peroxide (BPO)-containing acne products have put dermatologists in a challenging position. Patients are understandably concerned about the safety of their acne
In recent breaking news, concerns surrounding benzene contamination have resurfaced, sparking renewed health worries and heightened regulatory scrutiny. Valisure LLC, an independent laboratory facility, has revealed the results of its
JNJ-77242113 has been evaluated for its efficacy in the treatment of moderate-to-severe plaque psoriasis. An IL-23-receptor antagonist peptide, it selectively blocks interleukin-23 signaling and downstream cytokine production and can be
Findings from a recent analysis have revealed that the administration of intravenous ertapenem demonstrates improvement in clinical and inflammatory markers of hidradenitis suppurativa (HS) in addition to improved patient satisfaction.
LiVDerm’s annual South Beach Symposium (SBS) and Masters of Pediatric Dermatology (MOPD) Symposium recently concluded after an impactful few days of dermatology education. Healio was on site, providing coverage of
According to a recent study published in the Journal of Immunity, Inflammation, and Disease, combining topical corticosteroids with dupilumab can significantly help alleviate symptoms associated with atopic dermatitis (AD) in
A recent study evaluated the effects of a moisturizer containing 20% urea on patients with keratosis pilaris (KP) and found that it may help to improve the skin’s smoothness and
In a recent press release, Galderma announced that RelabotulinumtoxinA significantly improved glabellar and lateral canthal lines. Data from their Phase III READY-3 clinical trial reveal that a single dose of
According to a recent phase 2a randomized clinical trial, PF-07038124, a topical PDE4 inhibitor, is an effective and well-tolerated treatment for patients with atopic dermatitis (AD) and plaque psoriasis. “Topical
The U.S. Food and Drug Administration (FDA) has approved ZELSUVMIâ„¢ (berdazimer topical gel, 10.3%) from Ligand Pharmaceuticals Incorporated for the treatment of molluscum contagiosum in adults and pediatric patients aged
On December 19, Chiesi Global Rare Diseases announced that the U.S. Food and Drug Administration (FDA) approved FILSUVEZ® (birch triterpenes), a topical gel for the treatment of partial thickness wounds
Arcutis Biotherapeutics recently announced that the U.S. Food and Drug Administration (FDA) approved their new drug application for ZORYVE® (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in
The U.S. Food and Drug Administration (FDA) recently issued a notification to isotretinoin manufacturers to state that they must modify the iPledge Risk Evaluation and Mitigation Strategy (REMS). Originally implemented
Dermavant Sciences recently announced positive results from their phase 4 open-label clinical trial of VTAMA® (tapinarof) cream 1% for the treatment of plaque psoriasis in the head and neck region
Biopharmaceutical company, Almirall, recently announced in a press release that the European Commission (EC) has granted approval for EBGLYSSⓇ (lebrikizumab) for moderate-to-severe atopic dermatitis (AD) in patients 12 years and
The treatment and management of vitiligo can be challenging for both patients and their providers. Vitiligo carries a significant disease burden, both physically and mentally. Furthermore, due to the lack
A recent study published in the Journal of the American Academy of Dermatology sought to evaluate the prevalence of allergic contact dermatitis (ACD) in children with atopic dermatitis (AD). According
Hyperhidrosis (HH) is a condition characterized by excessive sweating beyond what is necessary for thermoregulation and affects millions of people worldwide. It can be a debilitating condition, often causing social
Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in adults. Cosentyx is the first interleukin-17A
Bausch Health has announced that the U.S. Food and Drug Administration (FDA) has approved IDP-126 (Cabtreoâ„¢) for the treatment of acne in patients aged 12 years and older. IDP-126 (clindamycin
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
